ProfileGDS5678 / 1442256_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 71% 70% 75% 79% 72% 75% 75% 75% 72% 76% 75% 72% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2658769
GSM967853U87-EV human glioblastoma xenograft - Control 24.472471
GSM967854U87-EV human glioblastoma xenograft - Control 34.4058670
GSM967855U87-EV human glioblastoma xenograft - Control 45.1068375
GSM967856U87-EV human glioblastoma xenograft - Control 55.5192979
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5330672
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8478575
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9738775
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0165375
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6396472
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0330276
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9459675
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5562972
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.172668